CLINICAL TRIALS PROFILE FOR DANICOPAN
✉ Email this page to a colleague
All Clinical Trials for danicopan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Achillion, a wholly owned subsidiary of Alexion | Phase 2 | 2017-03-31 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
| NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Achillion Pharmaceuticals | Phase 2 | 2017-03-31 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
| NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Alexion Pharmaceuticals | Phase 2 | 2017-03-31 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
| NCT03108274 ↗ | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants | Completed | Achillion, a wholly owned subsidiary of Alexion | Phase 1 | 2017-04-18 | The purpose of this study was to determine the potential drug interaction between danicopan (ACH-0144471) and midazolam, fexofenadine, and mycophenolate mofetil. This was a 3-part study, with each part being an open-label, fixed-sequence, 2-treatment study in healthy adult participants. |
| NCT03108274 ↗ | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants | Completed | Achillion Pharmaceuticals | Phase 1 | 2017-04-18 | The purpose of this study was to determine the potential drug interaction between danicopan (ACH-0144471) and midazolam, fexofenadine, and mycophenolate mofetil. This was a 3-part study, with each part being an open-label, fixed-sequence, 2-treatment study in healthy adult participants. |
| NCT03108274 ↗ | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants | Completed | Alexion Pharmaceuticals | Phase 1 | 2017-04-18 | The purpose of this study was to determine the potential drug interaction between danicopan (ACH-0144471) and midazolam, fexofenadine, and mycophenolate mofetil. This was a 3-part study, with each part being an open-label, fixed-sequence, 2-treatment study in healthy adult participants. |
| NCT03124368 ↗ | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | Completed | Achillion, a wholly owned subsidiary of Alexion | Phase 2 | 2017-08-09 | The primary objective of this study was to determine whether ACH-0144471 (also known as danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants with low C3 levels due to either C3G or IC-MPGN. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for danicopan
Condition Name
Clinical Trial Locations for danicopan
Trials by Country
Clinical Trial Progress for danicopan
Clinical Trial Phase
Clinical Trial Sponsors for danicopan
Sponsor Name
